Sponsors (20)
The bill strengthens and diversifies U.S. medical supply chains, regulatory cooperation, and procurement access—improving resilience and market opportunities—but does so at the risk of higher costs, added administrative complexity, potential limits on emergency flexibility, and some tradeoffs for regulatory discretion and global collaboration.
Hospitals, health systems, healthcare workers, and patients will face fewer shortages during public‑health emergencies because the bill promotes diversified suppliers, trusted trade partners, and expanded domestic production for critical medical goods.
Hospitals, providers, and government contractors will experience faster cross‑border movement and regulatory approvals for medical goods because the bill encourages regulatory harmonization and expedited procedures.
Small businesses, domestic suppliers, government contractors, and exporters will gain more opportunities to win government contracts and access foreign markets because the bill expands procurement access (including WTO/GPA steps) and requires partner compliance.
Taxpayers, patients, and small businesses could face higher costs because encouraging domestic production, supplier vetting, reshoring, and reduced tariff revenue may raise procurement prices and increase budgetary pressure.
Hospitals, patients, and national responders could lose flexibility during crises because reciprocal trade commitments, procedural review requirements, and certain agreement terms may limit the U.S. government's ability to restrict imports or act quickly in emergencies.
Federal agencies, state and local governments, and affected companies could face significant administrative burden and uncertainty because implementing, negotiating, and enforcing new procurement, IP, and regulatory commitments requires new procedures and may be delayed by future agreements or interagency requirements.
Based on analysis of 7 sections of legislative text.
Allows the President to negotiate "trusted trade partner" agreements to reduce tariffs and barriers on medical goods, with defined partner criteria, congressional review, and USTR monitoring.
Introduced March 18, 2025 by Nicole Malliotakis · Last progress March 18, 2025
Authorizes the President to negotiate and enter into "trusted trade partner" agreements with foreign countries to lower or eliminate duties and other import restrictions on medical devices, pharmaceuticals, and related medical goods to strengthen U.S. medical supply chain resilience. The bill sets criteria for partner selection, outlines permitted agreement provisions (including tariff removal, regulatory cooperation, procurement access, IP protections, and emergency exemptions), creates a multi-step congressional review process before agreements take effect, and requires ongoing monitoring and enforcement by the U.S. Trade Representative with prompt presidential action for noncompliance.